Clinical Trial Search

Primary: Family Planning Visit and Long-acting Reversible Contraception Use at Three and Six Month Follow-up by Condition. — 2; 7; 2; 7 Participants

Primary: Feasibility of Providing Intervention — 25; 22 Participants

Primary: Reproductive Life Goal Behavioral Intentions — 3.6; 2.7; 3.3; 3.0 score on scale

Primary: Percentage of Participants With Verified Prescription Contraceptive Use at the 6-month Assessment — 5; 14; 23 Participants — p=<.001

Primary: Percent of HIV Target Immune Cells Within Female Genital Mucosa and Blood — 26.6; 22.8; 16.9; 22.4 percentage of HIV target immune cells

Primary: Mean Serum Concentrations of Etonogestrel and Ethinyl Estradiol — 1275; 1240; 21.9; 14.8 ng/L

Primary: Percentage of Participants Reporting a Pregnancy — 0; 0.3 % of participants reporting pregnancy

Primary: Potential Efficacy: Effective Contraception Initiation Rates [Time Frame: Enrollment, 12 Weeks Post-enrollment (2 Weeks Post Close of Intervention)] — 14; 14 Participants

Primary: Maximum Serum Concentration Between Normal and Obese BMI Women Ingesting 1.5mg Levonorgestrel — 10.3; 5.57 ng/mL

Primary: Number of Premenopausal Women With Overweight/Obesity Who Initiated a COC vs. Continued NHC Use, Enrolled and Remained in This Study, and Completed Outcome Measures — 9…

Primary: Intention to Initiate Contraception — 59 Participants

Primary: Change in Contraceptive Knowledge Assessment (CKA) Score — 0.90; 1.6 scores on a scale — p=<0.0001

Primary: Maternal HIV Incidence — 0.38; 0.31 incidence/100 Person years

Primary: Continuation Rates — 82; 78; 83 participants

Primary: Number of Participants With Ovulation With Implant-alone — 7; 0 Participants

Primary: Serum Etonogestrel Concentrations — 164.0; 47.8 pg/mL

Primary: Feasibility of Application — 4.47; 4.52; 4.16; 4.26 units on a scale

Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L

Primary: Number of Women 'Prepared for Pregnancy\ — 3 participants

Primary: PrEP Uptake at Week 1 — 63 Participants

Primary: Change From Baseline in Insulin Sensitivity — -1.91; -5.63 min ^ -1 / mIU / L

Primary: All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule…

Primary: Number of Participants With Delay in Follicular Rupture Beyond 5 Days — 46; 43; 12 Participants

Primary: Percentage of Pregnancies Prevented (PPP) — 77.5; 36.9 percentage of pregnancies prevented — p=<0.0001

Primary: Contraceptive Use — 93.43; 94.46; 94.10 percentage of surveys — p=1.0

Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705

Primary: ABILITY TO FOLLOW POSTPARTUM TEENS FOR 1 YEAR. — 22; 16 Participants

Primary: Visits With PrEP Dispensation to Female Study Participants Reporting Sexual Behaviors or STI Symptoms — 211 Visits

Primary: Continuation at 1 Year — 21; 30 participants

Primary: The Number of Participants in Two Treatment Groups (1.5mg Levonorgestrel and 3mg Levonorgestrel) With no Follicle Rupture at 5 Days Within One Menstrual (Treatment)…